Intellia Therapeutics has announced it has secured $70 million in series B financing.
Intellia, based in Cambridge, Mass., is gene editing company focused on the development of curative medicines utilizing a developed biological tool known as the CRISPR/Cas9 system.
The funding round was led by OrbiMed HealthCare Fund Management. Additional investors included Fidelity Management and Research Company, Janus Capital Management, Foresite Capital, Sectoral Asset Management, EcoR1 Capital and founding investors Atlas Venture and Novartis.
Intellia indicated the proceeds from the financing will go toward accelerating the development of its pipeline, expand its platforms for gene editing and delivery, and strengthen its intellectual property portfolio.